Regencell Bioscience Holdings Ltd RGC

Shorted this company in the past. Made good sum.

[sungrin1309]

Shorted this company in the past. Made good sum.

Regencell Bioscience Limited’s (NASDAQ:RGC) is a bioscience *healthcare* company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.

The company has seen a good rise of over 300% since taking the company IPO in July 2021, and have seen on a roller coaster ride between euphoria and depression in the recent months.

Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).

As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.

(https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/)